Assembly Biosciences Ownership
| ASMB Stock | USD 13.02 0.81 6.63% |
Shares in Circulation | First Issued 2014-09-30 | Previous Quarter 6 M | Current Value 6 M | Avarage Shares Outstanding 2.6 M | Quarterly Volatility 1.5 M |
Assembly |
Assembly Stock Ownership Analysis
About 12.0% of the company shares are held by company insiders. The book value of Assembly Biosciences was presently reported as 4.09. The company recorded a loss per share of 6.89. Assembly Biosciences had not issued any dividends in recent years. The entity had 1:12 split on the 12th of February 2024. Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus infection in the United States. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California. Assembly Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 70 people. For more info on Assembly Biosciences please contact Jason JD at 833 509 4583 or go to https://www.assemblybio.com.Besides selling stocks to institutional investors, Assembly Biosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Assembly Biosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Assembly Biosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Assembly Biosciences Quarterly Liabilities And Stockholders Equity |
|
Assembly Biosciences Insider Trades History
About 12.0% of Assembly Biosciences are currently held by insiders. Unlike Assembly Biosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Assembly Biosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Assembly Biosciences' insider trades
Assembly Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Assembly Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Assembly Biosciences backward and forwards among themselves. Assembly Biosciences' institutional investor refers to the entity that pools money to purchase Assembly Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bridgeway Capital Management, Llc | 2024-09-30 | 14.5 K | State Street Corp | 2024-09-30 | 12.8 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 12.7 K | Citadel Advisors Llc | 2024-09-30 | 12.7 K | Palumbo Wealth Management Llc | 2024-12-31 | 11.4 K | Marquette Asset Management Inc. | 2024-12-31 | 9 K | Amundi | 2024-09-30 | 7.9 K | Jpmorgan Chase & Co | 2024-09-30 | 7 K | Barclays Plc | 2024-09-30 | 3 K | Armistice Capital, Llc | 2024-09-30 | 354 K | Vanguard Group Inc | 2024-09-30 | 200.5 K |
Assembly Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Assembly Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Assembly Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Assembly Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Schornstein Alexander over a year ago Purchase by Schornstein Alexander of 300000 shares of Assembly Biosciences | ||
Nicole White over a year ago Sale by Nicole White of 477 shares of Assembly Biosciences | ||
Schornstein Alexander over a year ago Assembly Biosciences exotic insider transaction detected | ||
Nicole White over a year ago Acquisition by Nicole White of 10000 shares of Assembly Biosciences subject to Rule 16b-3 | ||
Nicole White over a year ago Assembly Biosciences exotic insider transaction detected |
Assembly Biosciences' latest congressional trading
Congressional trading in companies like Assembly Biosciences, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Assembly Biosciences by those in governmental positions are based on the same information available to the general public.
| 2021-02-10 | Representative Chris Jacobs | Acquired Under $15K | Verify |
Assembly Biosciences Outstanding Bonds
Assembly Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Assembly Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Assembly bonds can be classified according to their maturity, which is the date when Assembly Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Assembly Biosciences Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
8K | 3rd of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 31st of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 23rd of December 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Assembly Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Assembly Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Assembly Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Assembly Biosciences Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assembly Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Assembly Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.89) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Assembly Biosciences is measured differently than its book value, which is the value of Assembly that is recorded on the company's balance sheet. Investors also form their own opinion of Assembly Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Assembly Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Assembly Biosciences' market value can be influenced by many factors that don't directly affect Assembly Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Assembly Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Assembly Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.